BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Topics » Financings, BioWorld

Financings, BioWorld
Financings, BioWorld RSS Feed RSS

Akoya Biosciences rakes in $50M to back CODEX, Phenoptics platforms

Dec. 5, 2019
By Liz Hollis
Menlo Park, Calif.-based Akoya Biosciences Inc. has scooped up $50 million in financing, with an eye toward growing via the expansion of commercial and operational resources and continuing product development activities around its platforms for spatial biology.
Read More

Cancer-focused Black Diamond raises $85M series C

Dec. 5, 2019
By Michael Fitzhugh
Tumor-agnostic therapy developer Black Diamond Therapeutics Inc. has completed an oversubscribed series C financing of $85 million. The Cambridge, Mass.-based company said proceeds will help it advance candidates targeting oncogenic driver mutations of the ErbB kinases in EGFR and HER2, starting with a combined phase I/II trial of its most advanced candidate next year.
Read More

4Teen4 closes $8M A round to test first-in-class cardiogenic shock drug

Dec. 5, 2019
By Cormac Sheridan
DUBLIN – 4Teen4 Pharmaceuticals GmbH raised €6.9 million (US$7.7 million) in a series A round to take procizumab, a first-in-class inhibitor of circulating dipeptidyl-peptidase 3 (cDPP3), into clinical trials for patients with cardiogenic shock.
Read More

Financings for Dec. 5, 2019

Dec. 5, 2019
Biopharmas raising money in public or private financings.
Read More

Propelling ahead, Civetta raises a $53M series A

Dec. 4, 2019
By Lee Landenberger
Civetta Therapeutics LLC will take a $53 million series A to advance its platform and programs based on beta-propeller proteins that mediate protein-to-protein interactions. Those proteins can become involved in cancers, neurodegeneration and metabolic disorders, with oncology being the company’s initial focus.
Read More

Imcheck closes $53M B round for antibodies targeting gamma delta T cells

Dec. 4, 2019
By Cormac Sheridan
DUBLIN – Imcheck Therapeutics SAS raised €48 million (US$53.2 million) in a series B financing round to move a pipeline of antibodies targeting gamma delta T cells into the clinic.
Read More

China’s Clover completes $43M series B

Dec. 4, 2019
By Elise Mak
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
Read More

Financings for Dec. 4, 2019

Dec. 4, 2019
Biopharmas raising money in public or private financings.
Read More

Financings for Dec. 3, 2019

Dec. 3, 2019
Biopharmas raising money in public or private financings.
Read More
Stock chart, upward arrow
IPO class of 2019

Biopharma stocks up 26% on average since debut with Karuna as top performer

Dec. 2, 2019
By Karen Carey
With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and pain.
Read More
Previous 1 2 … 312 313 314 315 316 317 318 319 320 … 330 331 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

    BioWorld Science
    Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
  • Medical illustration showing layers of a blood vessel

    Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

    BioWorld Science
    More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing